CytImmune nails down $1M for gold nanoparticle chemo treatment; Coagulated blood element produces drug delivery vehicle

> CytImmune has raised $1 million to fuel further clinical development of an experimental cancer treatment using gold nanoparticles to deliver chemotherapy drugs to tumors, MedCity News reports. Story

> Scientists have developed nanosized drug delivery vehicles made from fibrin, a natural biopolymer produced when blood coagulates, Nature India reports. Story (sub. req.)

> Burlington, MA-based Neuron Systems has gained the right to evaluate pSivida's ($PSDV) bioerodible Durasert drug delivery technology for back-of-the-eye diseases. Release

> Hospira ($HSP) gained FDA approval for its Symbiq 3.13 infusion pump, which is designed to deliver drugs through wireless communication and have better safeguards against medication errors. Release

And Finally... Xigo Nanotools, a nanoparticle device company, has raised further investment toward manufacturing a device designed to re-engineer the active particle ingredients in a drug to give it the same benefit at a lower concentration. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.